



A33081-R 072771.0106

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsang et al.

Serial No.: 09/633,034

Filed : August 4, 2000

For : MONOCLONAL ANTIBODIES AGAINST HUMAN COLON
CARCINOMA-ASSOCIATED ANTIGENS AND USES THEREFOR



Examiner: Helms, L.R.

Group Art Unit: 1642

SECOND DECLARATION OF DR. JEFFREY FASICK UNDER 37 C.F.R. §1.132

I hereby certify that this paper is being deposited on 8/10/05 with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Lisa B. Kole

Attorney Name

Signature

35,225

PTO Registration No.

8/10/05

Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
MAIL STOP RCE

Sir:

I, Dr. Jeffrey Fasick, declare the following:

1. I am Director of Science of International Bioimmune Systems, Inc. ("IBS"), assignee of the above-identified application.
2. I hold a Ph.D. from the Department of Biological Sciences of the University of Maryland, and have a substantial research background in the field of molecular biology, as illustrated by my *Curriculum Vitae*, a copy of which is attached hereto.
3. This declaration relates to studies that indicate that a chimeric version of monoclonal antibody 31.1 binds to the A33 antigen, but probably does not bind to the same epitope as the "A33" monoclonal antibody reported in the literature.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

4. The human glycoprotein A33 cDNA was cloned from COLO205 cells by PCR and transiently expressed in CHO cells. Cells transiently expressing A33 antigen were then subjected to immunohistochemical analysis with mAbs CHO31.1 and A33. As shown in FIGURE 1, both mAbs bind to CHO cells expressing A33 antigen (as seen in the +rA33 row) when compared to non-transfected cells (as seen in the -rA33 row) suggesting that both mAbs share a common antigen.

5. The panel of flow cytometry data shown in FIGURE 2 corroborates the immunohistochemistry discussed above, in that both mAbs CHO31.1 and A33 bind to CHO cells transiently expressing the A33 antigen. The panels show results of binding of the mAbs to full-length, truncated, and point mutated forms of the A33 antigen. Both mAbs bind in an identical fashion to both the full-length and mutated forms of the A33 antigen except for the N179D mutant as seen in the panel labeled +rA33:N179D. Here a distinct shift in the fluorescence intensity between the mAb CHO31.1 and mAb A33 spectra is seen. These results suggest that mAbs CHO31.1 and A33 do not share the same epitope on the A33 antigen.

6. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of any patent issuing from the above-captioned patent application.

Dated: July 12, 2005

By:

Jeffrey D. Pasick
Jeffrey Pasick

Jeffrey I. Fasick, Ph.D.

6 Jefferson Street
Port Washington, New York 11050

Cellular Phone: 646-491-0171
Email: FASICK_IBS@YAHOO.COM

1. Employment History

- 2003-Present **Director of Science**
International Bioimmune Systems, Inc.
- 225 West Community Drive Great Neck, New York 11021
Duties: In Charge of All R&D Labs and Personnel; Responsible for Lead Product Development
- 2002-03 **Senior Research Scientist**
- International Bioimmune Systems, Inc.
225 West Community Drive Great Neck, New York 11021
Research: Development of Immunotherapeutic mAbs Specific for Colon and Pancreatic Tumor Associated Antigens
- 1999-2002 **Scientific Consultant, Proctor and Gamble Pharmaceuticals**
G-Protein Coupled Receptor Group, Dr. Robert Barnett (Group Head)
Health Care Research Center
Proctor and Gamble Pharmaceuticals, Mason, Ohio 45040
Research: Cloning, Expression, and Purification of the Human Melanocortin-4 Receptor Gene
- 1998-2002 **Postdoctoral Fellow**
Laboratory of Professor Daniel D. Orian (Department Chair)
Department of Biochemistry and the Volen Center for Complex Systems
Brandeis University Waltham, Massachusetts 02454
Research: Molecular Mechanisms of Spectral Tuning in Mammalian Photoreceptor Visual Pigments

2. Education

- 1993-98 **Ph.D.**
Department of Biological Sciences
University of Maryland Baltimore County
Baltimore, Maryland 21250
- 1990-93 **M.S.**
Department of Biological Sciences
University of Maryland Baltimore County
Baltimore, Maryland 21250
- 1984-88 **B.S.**

Department of Ecology, Ethology, and Evolution
University of Illinois, Urbana-Champaign
Urbana, Illinois 61801

Experience / Accomplishments

Director of Science
June 2003-Present

International Bioimmune Systems, Inc.
Great Neck, New York

- Wrote Pre-IND briefing document for a Phase 1 clinical trial
- Represented sponsor and presented at Pre-IND meeting with the FDA
- Wrote the International Bioimmune Systems, Inc. Executive Summary Statement
- Produced the International Bioimmune Systems, Inc. Research Summary Presentation
- Evaluated/contracted out-sourcing partners for GMP manufacturing, tissue cross-reactivity testing, and animal studies per FDA recommendations
- Presented data, research, and records to potential investors and collaborators
- Presented current research at annual shareholders meetings
- Liaison for Principle Investigators for Phase 1 Clinical Trials
- Designed/implemented S.O.P. protocols
- Designed/implemented cGMP-like manufacturing protocols for immunotherapeutic mAbs
 - High expression/high viability in stirred reactor
 - Multi-step purification with robust viral removal
 - Aseptic Fill/Finish
 - Quality Control Testing
- Initiated and supervised the immunopurification of tumor associated antigen for identification by MALDI MS
- Initiated and supervised the characterization of immunotherapeutic mAbs by tissue cross reactivity testing, cell flow cytometry, cell based ELISA assays, cellular cytotoxicity assays, animal models including pharmacokinetic and toxicity studies
- Reviewed and edited patent applications, reissues, supplements, and office actions in coordination with patent attorneys and agents
- Created alliances with contractors for all facility maintenance, repairs, and services
- Collaborations: D. Webb (Wellesley University), Oncovation (Brooklyn, NY)

Senior Research Scientist
June 2002-June 2003

International Bioimmune Systems, Inc.
Great Neck, New York

- Developed cell line expressing immunotherapeutic mAb against colon/pancreatic cancer
 - Developed human-murine chimeric immunotherapeutic mAb
 - Developed stable expression immunotherapeutic mAb clones in CHO_{dhfr} cells
 - Amplified immunotherapeutic mAb expression levels in CHO_{dhfr} cells
 - Adapted mAb expressing CHO_{dhfr} cells to suspension and serum-free media
 - Created master and working cell banks
 - Deposited cell lines and plasmids with ATCC
 - Applied for patent supplement
- Developed clonogenic assay for immunotherapeutic mAbs
- Acquired expertise in column chromatography for protein purification
 - Immunoaffinity
 - Ion Exchange
 - Gel Filtration
 - FPLC
- Worked closely with outsourcing partner on the manufacturing of immunotherapeutic mAb

- Cloned and expressed tumor associated antigen specific for immunotherapeutic mAb
- Characterized the glycosylation pattern of tumor associated antigen
- Collaborations: I. Wang (Medical University of South Carolina), K. Tsang (National Cancer Institute), J. Schubert (Cell Trends, Inc.)

Postdoctoral Fellow
April 1998-June 2002

Brandeis University
Waltham, Massachusetts

- Developed large scale expression and purification system to study G-protein coupled receptors (GPCRs) from mammalian cells and suspension cultures
- Designed custom media utilized in N¹⁵ labelled protein expression system and expressed novel GPCRs for subsequent NMR analysis
- Performed site-directed mutagenesis to examine protein/ligand interactions and structural confirmations of GPCRs
- Performed G-protein and kinase binding assays to study protein activity
- Performed transgenic xenopus preparations for the expression of human GPCRs
- Performed DNA cloning, expression, and characterization of a variety of novel mammalian visual pigment genes
- Performed UV/visible light spectroscopy to analyze the spectral tuning properties of visual pigments
- Supervised graduate student rotation projects
- Collaborations: T. Smith (SUNY Stonybrook), M. Applebury (Harvard Medical School)

Research Fellow
September 1993-March 1998

University of Maryland Baltimore County
Baltimore, Maryland

- Prepared and screened cDNA libraries
- Conducted large- and small-scale plasmid preparation in E. coli
- Utilized stable and transient transfection techniques in mammalian cell lines
- Designed and implemented protocols to secure fresh tissue from dead stranded marine mammals
- Designed technique to dissect and process fresh tissue for total RNA and genomic DNA extraction
- Acquired expertise in PCR and RT-PCR; Maxam-Gilbert and Sanger dideoxy DNA sequencing; Northern, Southern, and Western blot analysis techniques, restriction fragment analysis; autoradiography,
- Performed phylogenetic analyses using PHYLIP, CLUSTAL V, MEGA, GCG Wisconsin package, and PAUP*
- Performed DNA analysis using FASTA, BLAST, and DNA Strider
- Skilled in Powerpoint, EXCEL, Kaleidagraph, Adobe, Chemdraw, Rasmol, and WebLab Veiwier
- Acquired expertise in light and electron microscopy (SEM & TEM).
- Utilized the training of computer generated neural networks
- Acquired expertise in performing immunoaffinity chromatography
- Collaborations: National Aquarium in Baltimore, National Marine Fisheries, Chicago Zoological Assn., H. Howland (Cornell University), Virginia Marine Science Museum, Smithsonian Institute National Museum of Natural History, Maryland DNR

Additional Training

- Protein Chromatography and PPLC Seminar Series, October 11-15, 2004, GE Healthcare (Amersham Biosciences)
- Good Manufacturing Practices, February, 2004, Schiff & Company, West Caldwell, NJ

- Cell & Tissue Reactor Engineering. July 15-18, 2002. Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN.
- Cell Culture Techniques. June 25-28, 2002. The Biotechnical Institute of Maryland, Inc. University of Maryland-Baltimore. Baltimore, MD.
- Workshop on Transgenics. June 2-3, 1999. Biotechnology Center, University of Connecticut, Storrs, CT.
- Workshop on Molecular Evolution. August 3-15, 1997. Marine Biological Laboratory, Woods Hole, MA.

3. Publications

- Fasick JJ, Applebury ML, Oprian DD. Spectral tuning in the mammalian short-wavelength sensitive cone pigments. *Biochemistry*. 2002 May 28;41(21):6860-5.
- Fasick, JJ, Robinson PR. Cloning and expression of dolphin opsin sequences and a mechanism of spectral tuning. Cell and Molecular Biology of Marine Mammals, Pfeiffer, C.J., Ed., Krieger Press, Melbourne, 2002.
- Fasick JJ, Robinson PR. Spectral-tuning mechanisms of marine mammal rhodopsins and correlations with foraging depth. *Vis Neurosci*. 2000 Sep-Oct;17(5):781-8.
- Fasick JJ, Lee N, Oprian DD. Spectral tuning in the human blue cone pigment. *Biochemistry*. 1999 Sep 7;38(36):11593-6.
- Cronin, TW, Fasick, JJ, Howland, HC. Video photoretinography of the eyes of the small odontocetes (*Tursiops truncatus*, *Phocoena phocoena*, and *Kogia breviceps*). *Mar. Mamm. Science* 1998 14: 584-90.
- Fasick JJ, Cronin TW, Hunt DM, Robinson PR. The visual pigments of the bottlenose dolphin (*Tursiops truncatus*). *Vis Neurosci*. 1998 Jul-Aug;15(4):643-51.
- Fasick JJ, Robinson PR. Mechanism of spectral tuning in the dolphin visual pigments. *Biochemistry*. 1998 Jan 13;37(2):433-8.

4. Published Abstracts

- Fasick, JJ, Oprian, DD. 2001. Spectral tuning in the mammalian short-wavelength sensitive cone visual pigments. *FASEB Biophysics* 80: 601a.
- Fasick, JJ, Robinson, PR. 1996. Molecular cloning and characterization of visual pigments in the bottlenose dolphin (*Tursiops truncatus*). *Society for Neuroscience* 22: 792.16.


Departmental Seminars/ Invited Talks

- 10th International Conference on Retinal Proteins. August 20-24, 2002. University of Washington, Seattle, WA. Title: Spectral Tuning in the Mammalian SWS-1 Cone Pigments.
- Department of Zoology, University of New Hampshire, Durham, NH. March 1, 2002. Title: Spectral Tuning in the Mammalian Short-Wavelength Sensitive Cone Pigments.
- 25th Annual Meeting of IMATA. October 20-25, 1997. Baltimore, MD. Title: The Visual Pigments of the Bottlenose Dolphin (*Tursiops truncatus*).


**Both mAbs CHO31.1 and A33 bind to CHO Cells Transiently
Transfected with Human Glycoprotein A33 cDNA**

Biotinylated mAb CHO 31.1

-rA33



+rA33



Biotinylated mAb A33




FIGURE 1

mAb CHO31.1 & mAb A33 Bind to CHO Cells Transfected with Full Length Human A33,
 Cytoplasmic Domain Deletion Mutant (CDD), and Non-Glycosylation Mutants




FIGURE 2

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.